These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38460107)

  • 1. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.
    Ozone M; Hirota S; Ariyoshi Y; Hayashida K; Ikegami A; Habukawa M; Ohshima H; Harada D; Hiejima H; Kotorii N; Murotani K; Taninaga T; Uchimura N
    Adv Ther; 2024 Apr; 41(4):1728-1745. PubMed ID: 38460107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH; Auerbach SH; Dang-Vu TT; Mishima K; Kumar D; Moline M; Malhotra M
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitioning insomnia patients from zolpidem to lemborexant: A multicenter, open-label study evaluating a next-dose transition approach to insomnia pharmacotherapy.
    Ahmad M; Kelly J; Montano CB; Kumar D; Perdomo C; Malhotra M; Amchin J; Moline M
    Sleep Med X; 2024 Dec; 7():100098. PubMed ID: 38312371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
    De Crescenzo F; D'Alò GL; Ostinelli EG; Ciabattini M; Di Franco V; Watanabe N; Kurtulmus A; Tomlinson A; Mitrova Z; Foti F; Del Giovane C; Quested DJ; Cowen PJ; Barbui C; Amato L; Efthimiou O; Cipriani A
    Lancet; 2022 Jul; 400(10347):170-184. PubMed ID: 35843245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists.
    Tachibana M; Kanahara N; Oda Y; Hasegawa T; Kimura A; Iyo M
    J Clin Sleep Med; 2024 Apr; 20(4):603-613. PubMed ID: 38063235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Juday T; Frech F; Atkins N
    J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.
    Kärppä M; Yardley J; Pinner K; Filippov G; Zammit G; Moline M; Perdomo C; Inoue Y; Ishikawa K; Kubota N
    Sleep; 2020 Sep; 43(9):. PubMed ID: 32585700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validated UPLC-MS/MS method for quantification of melatonin receptor agonists and dual orexin receptor antagonists in human plasma and breast milk: Application to quantify suvorexant and lemborexant in clinical samples.
    Ishikawa H; Furugen A; Nishimura A; Umazume T; Ishikawa S; Aoyagi R; Narumi K; Okamoto K; Takekuma Y; Sugawara M; Kobayashi M
    J Pharm Biomed Anal; 2024 Dec; 251():116432. PubMed ID: 39180895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapies for sleep disturbances in dementia.
    McCleery J; Sharpley AL
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009178. PubMed ID: 33189083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
    Landry I; Hall N; Aluri J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):365-373. PubMed ID: 35749758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder.
    Shigetsura Y; Imai S; Endo H; Shimizu Y; Ueda K; Murai T; Itohara K; Nakagawa S; Yonezawa A; Ikemi Y; Fukatsu S; Kitada N; Terada T; Nakagawa T; Matsubara K
    Clin Neuropharmacol; 2022 May-Jun 01; 45(3):52-60. PubMed ID: 35579484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
    Keks NA; Hope J
    Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort.
    Nishimura S; Nakao M
    J Med Econ; 2018 Jul; 21(7):698-703. PubMed ID: 29667471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users.
    Landry I; Hall N; Alur J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):374-382. PubMed ID: 35748777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
    Abad VC; Guilleminault C
    Drugs Aging; 2018 Sep; 35(9):791-817. PubMed ID: 30058034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial.
    Yardley J; Kärppä M; Inoue Y; Pinner K; Perdomo C; Ishikawa K; Filippov G; Kubota N; Moline M
    Sleep Med; 2021 Apr; 80():333-342. PubMed ID: 33636648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant.
    Okino K; Suzuki H; Tomioka H; Sanada K; Kawai K; Iwanami A; Inamoto A
    Hum Psychopharmacol; 2023 May; 38(3):e2868. PubMed ID: 36960814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis.
    Na HJ; Jeon N; Staatz CE; Han N; Baek IH
    Sleep; 2024 Feb; 47(2):. PubMed ID: 37950346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder.
    Dash A; Pinner K; Inoue Y; Hayashida K; Lim SC; Yun CH; Lan TH; Huang CL; Yardley J; Kubota N; Moline M
    Sleep Med X; 2022 Dec; 4():100044. PubMed ID: 35402894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.